These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 23687222)
1. Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission. Vardhanabhuti S; Acosta EP; Ribaudo HJ; Severe P; Lalloo U; Kumarasamy N; Taulo F; Kabanda J; Oneko O; Ive P; Sambarey P; Chan ES; Hitti J; Hong F; McMahon D; Haas DW; J Infect Dis; 2013 Aug; 208(4):662-71. PubMed ID: 23687222 [TBL] [Abstract][Full Text] [Related]
2. Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women. Chantarangsu S; Cressey TR; Mahasirimongkol S; Capparelli E; Tawon Y; Ngo-Giang-Huong N; Jourdain G; Lallemant M; Chantratita W J Antimicrob Chemother; 2009 Dec; 64(6):1265-73. PubMed ID: 19812066 [TBL] [Abstract][Full Text] [Related]
3. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. Haas DW; Gebretsadik T; Mayo G; Menon UN; Acosta EP; Shintani A; Floyd M; Stein CM; Wilkinson GR J Infect Dis; 2009 Mar; 199(6):872-80. PubMed ID: 19239339 [TBL] [Abstract][Full Text] [Related]
4. Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. Schipani A; Wyen C; Mahungu T; Hendra H; Egan D; Siccardi M; Davies G; Khoo S; Fätkenheuer G; Youle M; Rockstroh J; Brockmeyer NH; Johnson MA; Owen A; Back DJ; J Antimicrob Chemother; 2011 Jun; 66(6):1332-9. PubMed ID: 21441248 [TBL] [Abstract][Full Text] [Related]
13. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. Saitoh A; Sarles E; Capparelli E; Aweeka F; Kovacs A; Burchett SK; Wiznia A; Nachman S; Fenton T; Spector SA AIDS; 2007 Oct; 21(16):2191-9. PubMed ID: 18090046 [TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi. Dickinson L; Chaponda M; Carr DF; van Oosterhout JJ; Kumwenda J; Lalloo DG; Pirmohamed M; Heyderman RS; Khoo SH Antimicrob Agents Chemother; 2014; 58(2):706-12. PubMed ID: 24217698 [TBL] [Abstract][Full Text] [Related]
15. Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. McMahon DK; Zheng L; Hitti J; Chan ES; Halvas EK; Hong F; Kabanda J; Taulo F; Kumarasamy N; Bonhomme J; Wallis CL; Klingman KL; Hughes MD; Mellors JW Clin Infect Dis; 2013 Apr; 56(7):1044-51. PubMed ID: 23300238 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state. Fan-Havard P; Liu Z; Chou M; Ling Y; Barrail-Tran A; Haas DW; Taburet AM; Antimicrob Agents Chemother; 2013 May; 57(5):2154-60. PubMed ID: 23459477 [TBL] [Abstract][Full Text] [Related]
17. Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients. Mhandire D; Lacerda M; Castel S; Mhandire K; Zhou D; Swart M; Shamu T; Smith P; Musingwini T; Wiesner L; Stray-Pedersen B; Dandara C OMICS; 2015 Sep; 19(9):553-62. PubMed ID: 26348712 [TBL] [Abstract][Full Text] [Related]
18. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Rotger M; Colombo S; Furrer H; Bleiber G; Buclin T; Lee BL; Keiser O; Biollaz J; Décosterd L; Telenti A; Pharmacogenet Genomics; 2005 Jan; 15(1):1-5. PubMed ID: 15864119 [TBL] [Abstract][Full Text] [Related]
19. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Holzinger ER; Grady B; Ritchie MD; Ribaudo HJ; Acosta EP; Morse GD; Gulick RM; Robbins GK; Clifford DB; Daar ES; McLaren P; Haas DW Pharmacogenet Genomics; 2012 Dec; 22(12):858-67. PubMed ID: 23080225 [TBL] [Abstract][Full Text] [Related]
20. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Gatanaga H; Hayashida T; Tsuchiya K; Yoshino M; Kuwahara T; Tsukada H; Fujimoto K; Sato I; Ueda M; Horiba M; Hamaguchi M; Yamamoto M; Takata N; Kimura A; Koike T; Gejyo F; Matsushita S; Shirasaka T; Kimura S; Oka S Clin Infect Dis; 2007 Nov; 45(9):1230-7. PubMed ID: 17918089 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]